Furthermore, novel avenues are being explored in the domain of IL-23+ Tregs therapy, namely the generation of IL-23R-specific CAR Tregs for the management of Crohn’s disease [149], and the delineation of the role of Tregs in the pathogenesis of cancer. This evidence concerns the gene IL37 and cancer.